Orbis Research Presents Global Hypercalcemia Treatment Market 2017-2021 has been prepared based on an in-depth market analysis with inputs from industry experts.
Latest Research Report – Global Hypercalcemia Treatment Market 2017-2021
The Following Companies As The Key Players In The Global Hypercalcemia Treatment Market: AbbVie, Amgen, Merck, Novartis, and OPKO Health.
Other Prominent Vendors in the market are: DiaSorin, Rockwell Medical, Kyowa Hakko Kirin, and Fujirebio.
Commenting on the report, “One trend in market is combination therapy. Although the preference for hypercalcemia drugs in developed countries is increasing, the use of hypercalcemia drugs in combination with other therapies will help maintain the adoption rates. For instance, researchers have evaluated the use of combination drugs, which include pamidronate and calcitonin. This should increase the demand for hypercalcemia drugs in developed countries.”
According to the report, one driver in market is expanding label indications. As the market is dominated by generic products, label extensions will provide more opportunities for revenue generation. This is expected to propel the market growth substantially. Vendors are also increasingly focusing on developing drugs for segments such as parathyroidism and CKD. For instance, in 2016, OPKO Health received approval from the US FDA for Rayaldee (extended-release capsules) for the treatment of SHPT in adults with CKD and serum total 25-hydroxyvitamin D. Also, in November 2016, Amgen received approval from the EC for Parsabiv (etelcalcetide) to treat SHPT in adults with CKD on hemodialysis. In September 2015, Rockwell Medical Launched Calcitriol in the US for the treatment of iron replacement, SHPT, and hemodialysis. The increase in label indications will expand the scope of hypercalcemia, thereby driving the market growth.
Get a PDF Sample of Global Hypercalcemia Treatment Market Research Report @: http://www.orbisresearch.com/contacts/request-sample/270637
Further, the report states that one challenges in market is patent expiries of major drugs. Patent expiries result in the loss of an exclusive market for a drug, leading to a rapid decline in its sales. The introduction of low-cost drugs is likely to increase the competition in the market. The market has experienced the limited availability of branded products due to the patent expiry of major drugs such as Amgen’s Sensipar, which lost its patent in 2016. Similarly, AbbVie’s ZEMPLAR (paricalcitol) lost its patent in 2015, and Sanofi-Aventis US’s Hectorol (doxercalciferol), which was an intravenous for the treatment of SHPT, had lost its patent in 2014. Thus, the patent expiries of major drugs result in the decline of the market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
For Enquiry @: http://www.orbisresearch.com/contacts/enquiry-before-buying/270637 and to Place Purchase Order for this Report @: http://www.orbisresearch.com/contact/purchase/270637
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Follow Us on LinkedIn: https://www.linkedin.com/company/orbis-research